Regulatory decisions affecting biopharma products in development, including: Abbvie, Agenus, Algernon, Alnylam, Anheart, Astrazeneca, Aurinia, Bellerophon, Biocryst, Bluebird, Can-Fite, Cansino, Cstone, Cytodyn, Cytokinetics, Dicerna, Eiger, Eisai, Eli Lilly, Exelixis, Genentech, Gilead Sciences, Hansoh, Helsinn, Humanigen, Immunomic, Immutep, Inmed, Intelgenx, Intercept, Intrabio, Janssen, Jazz, Kadmon, Kempharm, Lupin, Mallinckrodt, Mylan, Neuren, Newron, Nicox, Novartis, Orchard, Orion, Paratek, Pfizer, Pharming, Pharnext, Recordati, Sage, Sanofi, Seelos, Spero, Synairgen, Takeda, Teva, Trevena, Valneva, Virometix, Zai Lab, Zealand, Zydus Cadila.

In order to redirect health care resources and protect patients during the COVID-19 pandemic, many drug companies have paused enrollment in some or all of their ongoing clinical trials.

It has been more than 200 years since British doctor James Parkinson first identified the symptoms of a condition that he termed shaking palsy; unfortunately, there is still no cure to the disease that carries his name.

In order to redirect health care resources and protect patients during the COVID-19 pandemic, many drug companies have paused enrollment in some or all of their ongoing clinical trials. But patients still in the studies need to be followed for safety and efficacy, creating challenges for the industry.